U.S. Stock Market Midday Update

Qualigen Therapeutics rose 63.49%. Based on recent important news:

1. On June 30, Qualigen Therapeutics released a new financial report showing significant progress in the development of innovative drugs, driving the stock price up by 63.49%.

2. On June 27, B of A Securities maintained its rating on Qiagen and raised the target price to $53, boosting market confidence in the biotechnology sector.

3. On May 21, the innovative drug sector rose overall, with 3SBio and Pfizer reaching a significant deal, further enhancing market sentiment.

Stocks with High Trading Volume in the Industry

Blueprint Medicines fell 0.01%, with increased trading volume. Based on recent key news:

1. On July 15, the short interest in Blueprint Medicines rose by 17.61%, leading to increased bearish sentiment in the market, putting pressure on the stock price.

2. On July 14, the well-known class action law firm Monteverde & Associates PC announced it would recover millions of dollars for shareholders, which, although not directly related to Blueprint Medicines, may raise investor concerns about legal risks.

3. On July 13, concerns about the overall outlook for the biopharmaceutical industry intensified, affecting the market performance of Blueprint Medicines.

CRISPR Therapeutics rose 3.52%, with increased trading volume. Based on recent important news:

1. On July 14, renowned investor William Miller upgraded CRISPR's rating to "Buy," expecting the company's future performance to outperform the market, driving the stock price up by 3.52%.

2. On July 15, despite some well-funded investors adopting bearish strategies, optimistic sentiment towards CRISPR remained dominant in the market.

3. On July 15, Benzinga's public options data showed increased investor interest in CRISPR, further supporting the stock price increase.

AbbVie rose 1.27%, with increased trading volume. Based on recent important news:

1. On July 13, the CNS field experienced a revival, with market size accelerating growth and innovative therapies breaking through, driving AbbVie's stock price up by 1.27%.

2. On July 15, analysts gave AbbVie a "Moderate Buy" rating, despite five other stocks being considered more valuable for investment.

3. On July 15, clinical trial research continued, with the market maintaining focus on AbbVie's R&D progress.

Stocks with High Market Capitalization in the Industry

Amgen rose 0.74%, with a market capitalization of $158.4 billion. Based on recent important news:

1. On July 16, Amgen expanded its rare disease pipeline through the acquisition of ChemoCentryx and Horizon Therapeutics, driving its stock price up by 0.74%.

2. On July 15, market analysts stated that Amgen was not on the recommended buy list and maintained a hold rating.

3. On July 14, analysts suggested focusing on other stocks, with Amgen rated as hold